Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.
Botulinum toxin type B (BTX-B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX-A) it has off-label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX-B has also been shown to be a safe and effective alternative for patients who are resistant to BTX-A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX-B use. In this study, we report on three individual patients who received BTX-B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX-B at remote sites.
Dubow
Jordan
J
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60025, USA.
Kim
Angela
A
Leikin
Jerrold
J
Cumpston
Kirk
K
Bryant
Sean
S
Rezak
Michael
M
D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000150:complications*; D001905:Botulinum Toxins / Q000009:adverse effects*; D019274:Botulinum Toxins, Type A; D005260:Female; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy; D014786:Vision Disorders / Q000139:chemically induced*
C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A